Toru Beppu1, Yasunori Emi2, Shoji Tokunaga3, Eiji Oki4, Ken Shirabe4, Shinichi Ueno5, Masafumi Kuramoto6, Akira Kabashima7, Ikuo Takahashi8, Hironori Samura9, Susumu Eguchi10, Yoshito Akagi11, Shoji Natsugoe12, Yutaka Ogata13, Yoshihiro Kakeji14, Hideo Baba1, Yoshihiko Maehara15. 1. Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan. 2. Department of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan. 3. Medical Information Center, Kyushu University Hospital, Fukuoka, Japan. 4. Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 5. Department of Clinical Oncology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan. 6. Department of Surgery, Kumamoto Social Insurance General Hospital, Kumamoto, Japan. 7. Department of Surgery, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan. 8. Department of Surgery, Matsuyama Red Cross Hospital, Ehime, Japan. 9. Department of Surgery I, Ryukyu University, Okinawa, Japan. 10. Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. 11. Department of Surgery, Kurume University School of Medicine, Kurume, Japan. 12. Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan. 13. Department of Surgery, Kurume University Medical Center, Kurume, Japan. 14. Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Kobe, Japan. 15. Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan maehara@surg2.med.kyushu-u.ac.jp.
Abstract
BACKGROUND/AIM: The Kyushu Study group of Clinical Cancer (KSCC) conducted phase II trials (KSCC0802-UMIN000001308) concerning liver resectability after first-line treatment of advanced liver-limited colorectal metastases (CRLM) by a prospective, multi-center study. PATIENTS AND METHODS: Patients received 6 cycles of mFOLFOX6 with bevacizumab followed by evaluating liver resectability. The primary end-point was liver resection rate. RESULTS: The 40 patients enrolled from September 2008 to August 2010. The median number of administration cycles was 6 (range=1-7). The liver resectability cases were 16/40 (40.0 %) and the number of R0 cases was 10 patients (25.0%). An overall response rate was 30.0% (95% CI=15.2%-44.8%). Median progression-free and overall survival of all patients was 9.7 months and 33.0 months), respectively. CONCLUSION: mFOLFOX6 with bevacizumab regimen is safe and effective for advanced liver-limited CRLM and might lead to high liver resectability. Copyright
BACKGROUND/AIM: The Kyushu Study group of Clinical Cancer (KSCC) conducted phase II trials (KSCC0802-UMIN000001308) concerning liver resectability after first-line treatment of advanced liver-limited colorectal metastases (CRLM) by a prospective, multi-center study. PATIENTS AND METHODS: Patients received 6 cycles of mFOLFOX6 with bevacizumab followed by evaluating liver resectability. The primary end-point was liver resection rate. RESULTS: The 40 patients enrolled from September 2008 to August 2010. The median number of administration cycles was 6 (range=1-7). The liver resectability cases were 16/40 (40.0 %) and the number of R0 cases was 10 patients (25.0%). An overall response rate was 30.0% (95% CI=15.2%-44.8%). Median progression-free and overall survival of all patients was 9.7 months and 33.0 months), respectively. CONCLUSION:mFOLFOX6 with bevacizumab regimen is safe and effective for advanced liver-limited CRLM and might lead to high liver resectability. Copyright